Compare TSLX & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | QURE |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 2014 | 2007 |
| Metric | TSLX | QURE |
|---|---|---|
| Price | $21.68 | $24.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $23.50 | ★ $58.55 |
| AVG Volume (30 Days) | 427.6K | ★ 2.8M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | ★ 9.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $464,512,000.00 | $15,751,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $158.05 |
| P/E Ratio | $10.66 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.58 | $7.76 |
| 52 Week High | $25.17 | $71.50 |
| Indicator | TSLX | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 43.01 |
| Support Level | $21.62 | $19.29 |
| Resistance Level | $22.00 | $28.50 |
| Average True Range (ATR) | 0.29 | 1.65 |
| MACD | -0.04 | 0.90 |
| Stochastic Oscillator | 6.39 | 67.30 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.